EGFR and non-small cell lung carcinoma: Interestingly, persistent activation of the ERK signaling pathway is a molecular mechanism of EGFR-TKI resistance in NSCLC, and many receptors have been found to induce acquired drug resistance through persistent activation of ERK signaling [31–34].